Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Liminatus Pharma, Inc. Class A Common Stock

LIMN

Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $2.84 – $3.11
Volume 20,607
Market cap $4M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for LIMN.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for LIMN.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Liminatus Pharma Announces Nasdaq Delisting Notification

Liminatus Pharma (LIMN) received a delisting notice from Nasdaq on May 20, 2026, after failing to meet minimum market value requirements ($50M MVLS and $15M MVPHS) within the 180-day compliance period. The company intends to appeal the decision before the Nasdaq Hearings Panel by May 27, 2026, which will stay any suspension pending the hearing.

Benzinga

Liminatus Pharma Announces Proposed Merger with InnocsAI to Expand Oncology Cell Therapy Pipeline

Liminatus Pharma announced a definitive merger agreement with InnocsAI LLC, a biotechnology company specializing in CAR-T and antibody-based oncology therapies. Under the agreement, InnocsAI members will receive 1.6 billion shares of Liminatus common stock at $0.20 per share, valuing the transaction at approximately $320 million. The merger aims to expand Liminatus' oncology pipeline with advanced cell therapy assets including IBC101 (bivalent CAR-T for B-cell malignancies) and INC101 (dual-antigen CAR-T for solid tumors), pending shareholder and regulatory approvals.

Benzinga

Liminatus Pharma Is Trending Overnight — Here's Why LIMN Stock Surged Over 79% In After-Hours Session

Liminatus Pharma (LIMN) shares surged 79.34% to $0.34 in after-hours trading following the announcement of a definitive merger agreement with InnocsAI LLC. The deal brings a clinical-stage oncology portfolio including CAR-T and solid tumor programs. However, the stock has declined 96.95% over the past 12 months and trades near its 52-week low, with technical indicators showing negative price trends across all timeframes.

Benzinga

Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering

Liminatus Pharma (NASDAQ: LIMN), a pre-clinical stage immuno-oncology company, announced the pricing of a public offering of 13.8 million shares and warrants at $0.29 per share, expected to raise approximately $4.0 million in gross proceeds. The offering is expected to close on February 18, 2026, with net proceeds to be used for working capital and advancement of the company's CD47-blockade therapeutic programs.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Aug 21, 20261-for-50reverse split